
	OMB APPROVAL
	OMB Number: 3235-0060
	Expires: April 30, 2009
	Estimated average burden hours per response ... 38.0

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 ORor 15(d) of ~~The~~ the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~June~~July 1311, 2006 (July 7, 2006)

Myogen, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-50438	84-1348020
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)


7575 West 103^rd Avenue, Suite 102
Westminster, Colorado		80021

(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (303) 410-6666

Not applicable

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 1.01 Entry into a Material Definitive Agreement.
	Item 7.01 Regulation FD Disclosure.
	Item 9.01 Financial Statements and Exhibits.
SIGNATURES
EXHIBIT INDEX
Poster
Press Release

INFORMATION TO BE INCLUDED IN THE REPORT

~~In accordance with General Instruction B.2. of Form 8-K, the information presented in this filing and furnished in the exhibit attached hereto shall not be deemed “filed” for purposes of~~ Section 181 of— ~~the~~Registrant’s ~~Securities~~Business ~~Exchange~~and ~~Act of 1934, as amended, nor shall it be deemed~~Operations ~~incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.~~

Item 1.01 Entry into a Material Definitive Agreement.

On July 7, 2006, we (“Myogen” or the “Company”) entered into an amendment and restatement of our Collaboration and Option Agreement (as amended and restated, the “Amended and Restated Collaboration Agreement”) with Novartis Institutes for BioMedical Research, Inc. (“Novartis”). In connection with the execution of the Amended and Restated Collaboration Agreement, Novartis exercised its right to extend the term of the collaboration for an additional two year period.

The Amended and Restated Collaboration Agreement provides Novartis with the exclusive option to our discoveries, with limited exceptions, ending October 2008 (relating to product candidates other than histone deacetylase inhibitor (HDACi) product candidates) and May 2008 (relating to HDACi product candidates). Thereafter, the collaboration can be extended by mutual agreement of the parties. Novartis has an early termination right which allows it to terminate the Collaboration Agreement with 60 days prior notice at any time (for product candidates other than HDACi product candidates) or at any time after November 23, 2006 (for HDACi product candidates). In addition, the collaboration may be terminated upon breach of applicable licenses, insolvency of either party, mutual written agreement or our sale to a competitor of Novartis.

Upon execution of a license for a product candidate, Novartis is obligated to fund all further development of that product candidate, make payments to us upon the achievement of certain milestones and pay us royalties for sales if the product is successfully commercialized. To date, Novartis has not licensed any drug targets or compounds under the terms of the collaboration. If Novartis enters into such a license in the future, upon the completion of Phase 2 clinical trials of any product candidates Novartis has licensed from us (with the exception of certain HDACi product candidates) for use in the field of heart muscle disease, we have the option to enter into a co-promotion and profit sharing agreement with them for that product candidate, subject to our reimbursement of a portion of the development expenses incurred up to that point plus a premium, our agreement to share the future development and marketing expenses, and elimination of the royalty payable to us.

The Amended and Restated Collaboration Agreement and related forms of license agreements will be filed as exhibits to our Form 10-Q for the period ending June 30, 2006.

Section 7 — Regulation FD

Item 7.01 Regulation FD Disclosure.

On ~~June~~July 1311, 2006, ~~additional~~we ~~results~~issued ~~from~~a ~~Myogen,~~press ~~Inc.’s~~release ~~Phase~~relating 2bto ~~clinical~~the ~~trial~~renewal of ~~darusentan in~~our ~~patients~~collaboration with ~~resistant hypertension were presented in a poster session at the European Society~~ ~~of Hypertension conference in Madrid, Spain~~Novartis. ~~The~~A ~~poster~~copy ~~as presented, entitled “Effects~~ of ~~Darusentan~~ ~~Treatment~~the onpress ~~Systolic~~release ~~Blood Pressure Control in Patients with Resistant Hypertension,”~~ is furnished as Exhibit 99.1 hereto, and may also be used in meetings with investors and analysts after the date hereof and possibly with immaterial modifications. The fact that the poster is being furnished should not be deemed an admission as to ~~the~~this ~~materiality~~Form ~~of any information contained therein~~8-K. ~~The information contained in the poster should be considered in the context of~~ ~~our filings with the Securities and Exchange Commission and other public announcements that we may make, by press release or otherwise, from time to time.~~

WeIn ~~expect~~accordance towith ~~make~~General Instruction B.2. of Form 8-K, the ~~poster~~information ~~available~~presented under this Item 7.01 and attached as Exhibit 99.1 shall not be deemed “filed” for ~~viewing~~purposes atof Section 18 of the Securities Exchange Act of 1934, as amended (the “~~Investor~~Exchange ~~Relations~~Act”), ~~section~~nor ofshall ~~our~~it be deemed ~~website~~incorporated ~~located~~by atreference ~~www.myogen.com,~~in ~~although~~any wefiling ~~reserve~~under the ~~right~~Securities toAct ~~discontinue~~of ~~that~~1933, ~~availability~~as amended, except as atexpressly ~~any~~set ~~time~~forth by specific reference in such a filing.

Some of the matters discussed in the poster contain forward-looking statements that involve significant risks and uncertainties, including summary statements relating to the results of our Phase 2b clinical trial of darusentan. Actual results could differ materially from those projected and we caution investors not to place undue reliance on the forward-looking statements contained in, or made in connection with, the poster.

Results from clinical trials, including the Company’s Phase 2b trial of darusentan, are not necessarily predictive of future clinical results. Top line results may not be confirmed upon full analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of the Company’s product candidates, including darusentan, may be discovered upon further analysis of trial data. If the Company’s product candidates do not meet safety or efficacy endpoints in clinical evaluations, they will not receive regulatory approval and the Company will not be able to market them. Even if the Company’s product candidates meet safety and efficacy endpoints, regulatory authorities may not approve them, the Company may not be able to successfully market them, or the Company may face post-approval problems that require the withdrawal of its product from the market. There can be no assurance that Myogen’s product candidates, including darusentan, will be proven safe and effective for use in humans. Abnormal elevations of liver function test results, including elevated serum aminotransferase concentrations, have been reported in trials of other endothelin receptor antagonists. The Company’s results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market its product candidates, competition from other biotechnology and pharmaceutical companies, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in clinical trials, whether caused by competition, adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company’s financial position and prospects. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Myogen is at an early stage of development and may not ever have any products that generate significant revenue.

It is our policy to update or reconfirm our public guidance only by issuing a press release or filing a publicly accessible document with the SEC. We generally plan to provide guidance as part of our annual and quarterly earnings releases but reserve the right to provide guidance at different intervals or to revise our practice in future periods. All information contained in the poster is as of June 13, 2006. We undertake no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in our expectations.

Section 9 — Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

99.1 ~~Poster~~ ~~entitled~~Press ~~“Effects~~Release, ofdated ~~Darusentan~~July ~~Treatment~~11, on2006, ~~Systolic~~entitled ~~Blood~~“Myogen ~~Pressure~~Announces ~~Control~~Extension ~~in Patients~~of ~~with~~Drug ~~Resistant~~Discovery ~~Hypertension~~Collaboration.”

Safe Harbor Statement; Forward Looking Statements.

This filing and the attached press release contain forward-looking statements that involve significant risks and uncertainties, including the statements relating to the potential for our discovery research program and collaboration with Novartis. Actual results could differ materially from those projected and we caution investors not to place undue reliance on the forward-looking statements contained therein.

Among other things, our results may be affected by difficulties or delays in our research and development program, difficulties or delays in our clinical trials, competition from other pharmaceutical and biotechnology companies, regulatory developments involving current and future products, our effectiveness at managing our financial resources and our ability to successfully develop and market our current products. Our discovery research program may not succeed in identifying additional therapeutic targets, product candidates or products. Novartis may choose to terminate or not renew the collaboration agreement in the future, possibly delaying our development programs and increasing our operating loss. If our product candidates, including darusentan and ambrisentan, do not meet the safety or efficacy endpoints in clinical evaluations or do not receive regulatory approval, we will not be able to market them. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue one or more of our drug development, discovery research or drug commercialization programs. We are at an early stage of development and may not ever have any products that generate significant revenue.

Additional risks and uncertainties relating to the company and our business can be found in the “Risk Factors” section of our Form 10-K for the year ended December 31, 2005 and our periodic reports on Form 10-Q and Form 8-K. We are providing the information contained in this release as of the date of the release and do not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated ~~June~~July 1311, 2006


		MYOGEN, INC.
	By:	/s/ Andrew D. Dickinson
		Andrew D. Dickinson
	Its:	Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.		Description		~~Description~~
99.1	~~99.1~~	Press Release, dated July 11, 2006, entitled “Myogen Announces Extension of Drug Discovery Collaboration.”		~~Poster entitled “Effects of Darusentan Treatment on Systolic Blood Pressure Control in Patients with Resistant Hypertension.”~~

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Filing Compare · MYOGEN INC